New modalities in the treatment of ocular allergy

International Ophthalmology Clinics

Volumn 43, Issue 1, 2003, Pages 105-110

  Ashrafzadeh, Amin ^a   Raizman, Michael B ^a  

^a TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHISTAMINIC AGENT; CHEMOKINE; CHEMOKINE RECEPTOR CCR1; CHEMOKINE RECEPTOR CCR3; CYCLOSPORIN A; CYTOKINE; EOTAXIN; IMMUNOGLOBULIN E; INTERLEUKIN 1; INTERLEUKIN 1 RECEPTOR; INTERLEUKIN DERIVATIVE; LEUKOTRIENE RECEPTOR BLOCKING AGENT; LORATADINE; MONTELUKAST; RANTES; TACROLIMUS; ZAFIRLUKAST; ZILEUTON;

ALLERGIC DISEASE; ALLERGIC REACTION; ARTICLE; DRUG EFFICACY; DRUG INHIBITION; DRUG POTENTIATION; DRUG RECEPTOR BINDING; EYE DISEASE; EYE PAIN; EYELID DISEASE; HISTAMINE RELEASE; HUMAN; IMMUNOGLOBULIN BLOOD LEVEL; MAST CELL; PRIORITY JOURNAL; TH2 CELL; VISUAL IMPAIRMENT;

EID: 0037412720     PISSN: 00208167     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004397-200343010-00012     Document Type: Article

References (20)

1. Fineman SM. The burden of allergic rhinitis: beyond dollars and cents. Ann Allergy Asthma Immunol 2002;88(Suppl):2-7
2. Nishimura A, Campbell-Meltzer RS, Chute K, et al. Genetics of allergic disease: evidence for organ-specific susceptibility genes. Int Arch Allergy Immunol 2001;124:197-200
3. Fukagawa K, Okada N, Fujishima H, et al. CC-chemokine receptor 3: a possible target in treatment of allergy-related corneal ulcer. Invest Ophthalmol Vis Sci. 2002;43:58-62
4. Keane-Myers AM, Miyazaki D, Liu G, et al. Prevention of allergic-eye disease by treatment with IL-1 receptor antagonist. Invest Ophthalmol Vis Sci. 1999;40:3041-3046
5. Casale TB, Condemi J, LaForce C, et al. Effect of omalizumab on symptoms of seasonal allergic rhinitis: a randomized controlled trial. JAMA. 2001;286:2956-2967
6. Adelroth E, Rak S, Haahtela T, et al. Recombinant humanized mAb-E25, an anti-IgE mAb, in birch pollen-induced seasonal allergic rhinitis. J Allergy Clin Immunol. 2000;106:253-259
7. Milgrom H, Fick RB, Su JQ et al. Treatment of allergic asthma with monoclonal anti-IgE antibody. N Engl J Med 1999;341:1966-1973
8. Berger WE. Monoclonal anti-IgE antibody: a novel therapy for allergic airway disease. Ann Allergy Asthma Immunol 2002;88:152-161
9. O'Shaughnessy KM, Wellings R, Gilles B, Fuller RW. Differential effects of fluticasone proprionate on allergen-evoked bronchoconstriction and increased urinary leukotriene E4. Am Rev Respir Dis 1993;147:1472-1476
10. Kagi MK. Leukotriene receptor antagonists - a novel therapeutic approach in atopic dermatitis? Dermatology 2001;203:280-283
11. Donnelly AL, Glass M, Minkwitz MC, Casale TB. The leukotriene D4-receptor antagonist, ICI 204-219, relieves symptoms of acute seasonal allergic rhinitis. Am J Respir Crit Care Med 1995;151:1734-1739
12. Meltzer EO. Clinical evidence for antileukotriene therapy in the management of allergic rhinitis. Ann Allergy Immunol 2002;88(Suppl):23-29
13. Creticos P, Knobil K, Edwards LD, et al. Loss of response to treatment with leukotriene receptor antagonists but not inhaled corticosteroids in patients over 50 years of age. Ann Allergy Asthma Immunol 2002;88:401-409
14. Stroms WW. Rethinking our approach to allergic rhinitis management. Ann Allergy Asthma Immunol 2002;88(Suppl):30-35
15. Sperr WR, Agis H, Semper H, et al. Inhibition of allergen-induced histamine release from human basophils by cyclosporin A and FK-506. Int Arch Allergy Immunol 1997;114:68-73
16. Schreiber SL, Crabtree GR. The mechanism of action of cyclosporin A and FK506. Immunol Today 1992;13:136-142
17. Hatfield SM, Roehm NW. Cyclosporine and FK506 inhibition of murine mast cell cytokine production. J Pharmacol Exp Ther 1992;260:680-688
18. Whitcup SM, Chan CC, Luyo DA, et al. Topical cyclosporine inhibits mast cell-mediated conjunctivitis. Invest Ophthalmol Vis Sci. 1996;37:2686-2693
19. Hingorani M, Calder VL, Buckley RJ, Lightman S. The immunomodulatory effect of topical cyclosporin A in atopic keratoconjunctivitis. Invest Ophthalmol Vis Sci. 1999;40:392-399
20. Hingorani M, Moodaley L, Calder VL, et al. A randomized, placebo-controlled trial of topical cyclosporin A in steroid-dependent atopic keratoconjunctivitis. Ophthalmology 1998;105:1715-1720